Drug Utilization Review Board
Meeting Agenda
Thursday, January 8, 2026
7:15 a.m. to 8:30 a.m.
Google Meet joining info
Video call link: meet.google.com/zue-rrqz-rpb
Or dial: (US) +1 904-900-0180 PIN: 172 873 306#
Persons who wish to address the DUR Board may contact Luis Moreno at lmoreno@utah.gov prior to the meeting, or sign up to provide comments at the meeting. Public comments will be limited to 3 minutes per speaker or organization due to time constraints.
1) Call to order - Sharon Weinstein, MD
a) Welcome and Introductions
b) Review and Approval of Minutes
c) Housekeeping - Luis Moreno, PharmD
2) Prior Authorization Updates - Luis Moreno, PharmD
3) Review Topic
a) Combination Treatment with Botox and a CGRP Antagonist in the Setting of Chronic Migraine - Monet Luloh, PharmD
i) Committee Discussion/Questions
ii) Committee Action
4) Public Comment
a) Axsome Therapeutics: Symbravo (meloxicam/rizatriptan) - Kyle Knudsen, PharmD
5) Review New Prior Authorization Criteria
a) Auvelity (dextromethorphan and bupropion), Fetzima (levomilnacipran), Trintellix (vortioxetine), Viibryd (vilazodone) - Skylar Fenton, PharmD
i) Committee Discussion/Questions
ii) Committee Action
b) Qelbree (viloxazine) - Kyu Yun Park, PharmD
i) Committee Discussion/Questions
ii) Committee Action
c) Updates for Zurzuvae (zuranolone) - Iris Wan, PharmD
i) Committee Discussion/Questions
ii) Committee Action
d) Filsuvez (birch triterpenes) - Luis Moreno, PharmD
i) Committee Discussion/Questions
ii) Committee Action
6) Next Meeting
a) Date: February 12, 2026
b) Topic: New Prior Authorization Reviews
7) Adjourned - Sharon Weinstein, MD
Notice of Special Accommodations (ADA)
In compliance with the Americans with Disabilities Act, individuals needing special accommodations (including auxiliary communicative aids and services) during this meeting should notify Luis Moreno at 801-538-6155.
Notice of Electronic or Telephone Participation
Video call link: meet.google.com/zue-rrqz-rpb
Or dial: (US) +1 904-900-0180 PIN: 172 873 306#